Ceruloplasmin (CP) is a copper-containing glycoprotein that carries approximately 90% of plasma copper. CP contains six copper atom binding sites and is prone to transfer its copper atoms to tissues, however it is not essential for copper transport. In cultured endothelial cells, CP release of copper in the cytosol inhibits nitric oxide synthase activation, and this may be important for regulating vascular tone in blood vessels. In addition to its copper binding role, CP has also been shown to have ferroxidase activity, which involves conversion of ferrous to ferric iron. The iron metabolism disorder aceruloplasminemia results from mutations in CP and is characterized by massive iron deposits in liver, pancreas, brain, retina, and other tissues. CP is expressed in the liver, the splenic reticuloendothelial system, the bronchiolar epithelium of the lung, and the retina and brain. The cell-specific expression of CP in neural tissues may account for the neuropathologies associated with aceruloplaminemia, while the wide expression pattern of CP may demonstrate its importance in the regulation of copper and iron levels in many tissues.
This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.